Reuters exclusively reported six-week sprint got Indian-made AstraZeneca vaccine approved in Canada

Reuters exclusively reported how problems at AstraZeneca Plc’s European production site in January kicked off a six-week push to get a version of its COVID-19 vaccine made at an Indian facility approved by Canada’s drug regulator. In late February, when Health Canada approved AstraZeneca’s COVID-19 vaccine, it also cleared a version of the shot made by the Serum Institute of India (SII). SII filed the application with a Canadian partner, Verity Pharmaceuticals. After the approval, Canada said it agreed to buy 2 million vaccine doses from Verity and Serum by mid-May, enough to vaccinate as much as 2.7% of its population. 

Article Tags
Topics of Interest: Health
Type: Reuters Best
Sectors: Pharmaceuticals & Healthcare
Regions: North America
Countries: Canada
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Major Global Story
Sign up for email updates

Sign up for email updates